Drug-pricing event ends abruptly when a pharma executive collapses behind the President.

The President held a televised event in the Oval Office on Thursday afternoon to announce that he had solved the cost of health care in America. The event was scheduled to feature deals with Regeneron, Novo Nordisk, Eli Lilly, and a long line of pharmaceutical executives standing politely behind him while he talked.

Mid-announcement, one of the executives, a senior man from Novo Nordisk, collapsed. He went down on the carpet of the Oval Office, behind the President, while the cameras kept rolling. The event was suspended. The man received medical attention. The press was ushered out.

Hon. There is a tell, every once in a while, where the room itself tries to give you a hint.

Earlier in the same event, before the collapse, the President had appeared to nod off briefly while a different executive talked about Alzheimer’s. The clip went around. The White House said he was “listening attentively.” He was, in the way that you are attentive at the dentist’s office while waiting on the second drill.

The deals are real. Regeneron and Novo Nordisk did agree to lower their list prices on certain drugs in exchange for the administration’s friendly tariff posture and the Most Favored Nation framework. The actual savings, when economists got to look at it that weekend, were narrower than the headline. The drugs in question were already discounted at most major insurers and pharmacy benefit managers. The new “deal” applied to a smaller and more expensive cash-pay channel that fewer Americans use.

The grocery store still costs what the grocery store costs. The insulin still costs more here than in Toronto. The man who collapsed got up and left under his own power, which is more than a lot of people can say about their pharmacy bill.

You ever notice how the announcements are always about the deal, never about the price you actually paid this week.

That ought to concern you.